Skip to content

Magnesium sulfate as an adjunct to cooling of babies who do not cry at birth.

Magnesium sulfate as an adjunct to therapeutic hypothermia in the management of term infants with hypoxic ischemic encephalopathy: A randomized controlled trial.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/06/014594
Enrollment
134
Registered
2018-06-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P916- Hypoxic ischemic encephalopathy [HIE] Health Condition 2: null- Term infants with Hypoxic Ischemic Encephalopathy

Interventions

Intervention1: Magnesium sulfate and therapeutic hypothermia: Term infants with hypoxic ischemic encephalopathy will receive magnesium sulfate as an adjunct to therapeutic hypothermia Magnesium sulfa

Sponsors

JIPMER Puducherry
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria A plus B and any one of C A. Inborn babies with Gestational age more than or equal to 37 weeks with Arterial blood gas(Umbilical cord or 1st postnatal hour) pH less than or equal to 7.0 or base deficit more than or equal to 12 meq/L B. Presence of moderate to severe encephalopathy C. Any one of the below mentioned criteria: 1. APGAR less than or equal to 5 at 10 minutes 2. Evidence of fetal distress 3. Assisted ventilation for at least 10 minutes after birth 4. Evidence of any organ dysfunction 5. History of acute perinatal event

Exclusion criteria

Exclusion criteria: Exclusion criteria Infants more than 6 hours of age

Design outcomes

Primary

MeasureTime frame
Neonatal mortality and/or abnormal neurodevelopmental outcome at 1 year of ageTimepoint: Neonatal mortality at 28 days of life and abnormal neurodevelopmental outcome at 1 year of age

Secondary

MeasureTime frame
a.Neonatal mortality b.Major neurodevelopmental disability at 1 year of age c.Hospital course and discharge status-seizure, Anti-epileptic requirement d.Adverse effects-Hypotension, respiratory depression, Hypermagnesemia e.Oxidative stress marker ( serum level of Malondialdehyde and Total antioxidant status) Timepoint: Neonatal mortality-28 days of life Major neurodevelopmental outcome-1 year of age Hospital course and discharge status-at discharge adverse effects-first 72 hours of life Oxidative stress marker-at birth and at 72 hours of life

Countries

India

Contacts

Public ContactDr Adhisivam B

JIPMER, Puducherry

adhisivam1975@yahoo.co.uk9488822113

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 14, 2026